It's the second such finding from U.S. health officials in a week...
Demand for the drugs has surged, even though health experts caution there's insufficient data about their long-term effects and how they work in certain populations.
The FDA said it will next review postmarketing data in its Sentinel system, including health insurance claims and patient health records.
[
add
]
[
|
|
...
]